# Deutsche Venture Capital

> Deutsche Venture Capital is a VC fund backing Biotechnology and Manufacturing. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: München, Germany
- Total investments: 10
- Last investment: May 2008
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dvc-deutsche-venture-capital/about/
- Website: http://www.dvcg.de

Deutsche Venture Capital is a VC fund in München focused on Biotechnology and Manufacturing. DVC Deutsche Venture Capital, a venture capitalist based in Munich, focuses primarily on European growth companies in the areas of information, telecommunication, semiconductor and industrial technologies as well as life sciences. In the field of life sciences DVC invests in the development of therapeutic and diagnostic products as well as inplatform and medical technologies. DVC’s total administrated fund volume amounts to 300 million Euro. For investments in private companies, DVC invests approximately 1 - 10 million Euro as lead investor or, in the case of larger financing rounds, as co-lead investor. DVC is a “value-added” financial investor. Each sector team consists of experienced investment managers with relevant backgrounds. Since its formation in 1998, DVC has invested in approximately 70 companies.

## Contacts

5 contacts available for Deutsche Venture Capital. Shizune tracks 1 team members at Deutsche Venture Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/deutsche-venture-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 40% |
| Manufacturing | 3 | 30% |
| Medical | 2 | 20% |
| Software | 2 | 20% |
| Health Care | 2 | 20% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 30% |
| Series C | 3 | 30% |
| Series D | 2 | 20% |
| Funding Round | 2 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 5 | 50% |
| United States | 2 | 20% |
| Saint-Martin (France) | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Sylvia Brahner | Legal Counsel | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MergeOptics | MergeOptics GmbH, was founded in Germany, in September 2000. The company develops highly integrated components for the rapidly growing high-speed fiber optic data transfer market. The company integrates optical components (lasers, modulators and photo diodes) with high-frequency electrical circuits to create compact modules that operate withindustry standard optical and electrical interfaces. MergeOptics' business objective is to specialize in high-speed optical products that are world-class for both integration and performance. MergeOptics maintains partnerships with several leading German Universities and research facilities, including the prestigious Heinrich-Hertz-Fraunhofer Institute in Berlin, Germany. | $8.3M | Series D | May 02, 2008 |  |
| VoluBill | VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform,which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia. | $14.8M | Series D | Sep 25, 2007 |  |
| Dolthera GmbH | Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. Withthis business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company.Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential. | $15.9M | Series B | Aug 12, 2005 |  |
| VoluBill | VoluBill S.A. provides real-time monitoring, control, and charging software to communication providers. It provides CHARGE-IT that enables real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a network charging, control, and policy enforcement platform; and CHARGE-IT Dynamic Charging Platform,which enables real-time, pre-pay, post-pay, and now-pay charging and control of data services. The company offers solutions to fixed, mobile, and fixed mobile convergent operators. VoluBill S.A. was founded in 2001 and is based in Montbonnot Saint Martin, France with additional offices in Europe and Asia. | $12.1M | Series C | Jan 17, 2005 |  |
| Epigenomics | Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions ofindividuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. | $23M | Series C | Apr 03, 2003 |  |
| Cardion | Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen. | $12.6M |  | Sep 23, 2002 |  |
| Onix Microsystems | OniX Microsystems designs, develops, and supplies micro-electro-mechanical systems (MEMS)-based all-optical switching engines for telecommunications equipment suppliers. Its products cover optical switching needs, including network protection and provisioning, optical add and drop multiplexing, and optical cross connects. It also offers MEMS designand photonic packaging services. OniX Microsystems was founded in 1998 and was headquartered in Richmond, California. | $95M | Series C | Aug 06, 2001 |  |
| Develogen AG | Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States. | $43.9M | Series B | Apr 18, 2001 |  |
| BigMachines | BigMachines is the global leader in enabling B2B sales, helping companies sell more and sell faster. BigMachines' award-winning on-demand configurator, pricing and quoting, proposal generator, and B2B eCommerce software solutions empower sales across customers' channels by streamlining their sales processes from opportunity to order.Using BigMachines software, sales teams and channels can quickly configure products, generate quotes and proposals, manage complex pricing, generate legal contracts, and manage orders. BigMachines offers extensive reporting capabilities and easily integrates to leading CRM and ERP systems, including those from salesforce.com, Oracle, Microsoft and SAP. BigMachines' rapidly growing customer base includes global leaders such as Kodak's GCG, Siemens, Ingersoll Rand, and NTT Communications, as well as innovative growth companies such as Acme Packet and Voltaire. | $29M | Series B | Mar 19, 2001 |  |
| Epigenomics | Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions ofindividuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. | $24.1M |  | Nov 14, 2000 |  |

10 of 10 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Argo Global Capital](https://shizune.co/investors/profile/argo-global-capital) — VC Fund, 2 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Deutsche Venture Capital invest in?

Deutsche Venture Capital invests primarily in Biotechnology, Manufacturing and Medical startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Deutsche Venture Capital?

Public channels for Deutsche Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Deutsche Venture Capital?

The team at Deutsche Venture Capital includes Sylvia Brahner (Legal Counsel). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co